Goodwin advised Playbook on the deal. Playbook closed its $7 million Series A led by Telstra Ventures, with support from Playbook’s founding venture studio Atomic. Based...
Playbook’s $7 Million Series A
Cubist’s $7 Million Seed Round
Goodwin Procter advised Cubist Inc. on the deal. Cubist Inc. announced its $7 million seed round. The round was led by Polychain Capital, with participation from venture...
SPACE ID’s $10 Million Strategic Funding Round
Goodwin Procter advised Polychain Capital on the deal. Polychain Capital announced its lead investment in SPACE ID’s $10 million strategic funding round, with dao5 also participating. Polychain,...
Cruz Foam’s $18 Million Series A Funding Round
Goodwin Procter advised Cruz Foam on the deal. Cruz Foam announced its $18 million Series A funding round. The round was led by Helena, with participation by...
nxyz’s $40 Million Series A Financing Round
Goodwin advised nxyz on the deal. Nxyz announced its $40 million Series A financing round. nxyz is a web3 platform that enables lightning-fast data infrastructure for blockchains....
Vespene Energy’s $4.3 Million Financing Round
Goodwin Procter advised Polychain Capital on the deal. Polychain Capital announced its lead investment in Vespene Energy’s $4.3 million financing round. Polychain Capital is a premier investor...
Pluto’s $4 Million Seed Round
Goodwin Procter advised at.inc/ on the deal. at.inc/ acted as lead investor in a $4 million dollar seed round in Pluto. The round included Switch Ventures...
Hermeus’ $100 Million Series B Financing Round
Goodwin Procter advised Sam Altman on the deal. Sam Altman acted as the lead investor in Hermeus’ $100 million Series B financing round. Sam Altman is...
Ventyx’s $174 Million IPO
Wilson Sonsini Goodrich & Rosati advised Ventyx on the deal. Ventyx Biosciences, a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living...
858 Therapeutics’ $60 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised New Enterprise Associates (NEA) and Versant Ventures on the deal. 858 Therapeutics announced the completion of a $60 million Series...
ADARx’s $75 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised SR One Capital Management on the deal. ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA targeting therapeutics, announced the completion...
Stablix Therapeutics’ $63 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Versant Ventures and NEA on the deal. Stablix Therapeutics announced a $63 million Series A financing. The funding round was...